Abbie Celniker, Ph.D.
“Every day here is like being on an innovation adventure with the smartest and most creative people you have ever met.”
Abbie has over 30 years of experience in Senior R&D and Executive leadership roles. As partner at Third Rock Ventures, she focuses on the formation, development and strategy of portfolio companies. She has a strong commitment to culture, and prioritizes establishing experienced, diverse teams.
Prior to joining the firm, she served as president and CEO of Eleven Biotherapeutics (now Sesen Bio) since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion’s executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals (now Takeda) and the vice president of protein technologies of the Wyeth Research facilities. She is a member of the board of directors of Abata Therapeutics and Flare Therapeutics. She has a B.A. in biology from the University of California, San Diego, and a Ph.D. in molecular biology from the University of Arizona.
- B.A., Biology, University of California, San Diego
- Ph.D., Molecular Biology, University of Arizona
- Tracy Williams
- Senior Executive Assistant
- East Coast